Just For [Young Frankenstein's] Old Time's Sake -- Another Keytruda® Collab, Announced Today -- Power Alley Stuff... This Time: Adagene, Out Of China.

I do not mean to poke fun at such serious and likely life saving human bio-science. . . but now I'm suffering through a brain/ear-worm, from all the re-conjured lines. . . of the immortal Mel Brooks classic -- "Young Frankenstein." [The company's CSO (at right) looks. . . just a bit like. . . Gene Wilder, no?]

In any event, and more directly, here is the latest in a true armada of clinical trials, testing Merck's pembrolizumab with lots of other monoclonal antibodies -- to enhance the effects of the wonder drug, in solid organ tumors. Do go read it all, but here's a bit, from PharmaLetter:

. . .This clinical study builds on the promising monotherapy and combination therapy data from a Phase I trial of ADG106. Engineered using Adagene’s proprietary NEObody platform technology, ADG106 is a fully human, ligand-blocking, agonistic anti-CD137 immunoglobulin G4 (IgG4) monoclonal antibody (MAb), said Adagene.

“We look forward to working closely with Merck and combining ADG106 with Keytruda”, said Dr Steven Fischkoff, interim chief medical officer of Adagene, who noted: “Together with our novel mechanism of action, extensive preclinical and strong clinical data generated to date, we believe ADG106 is an ideal candidate to combine with an anti-PD1 antibody to potentially create a new therapeutic option for cancer patients with unmet medical needs.”

Just last month, Adagene reached agreement with Merck on two open-label, dose escalation and expansion clinical studies to evaluate Adagene’s anti-CTLA-4 MAb product candidates, ADG116 and ADG126, in combination with Merck’s Keytruda for patients with advanced/metastatic solid tumors. . . .

Now you know. . . "The brain? Yes, it was. . . Abbey, somone. . . Oh -- Right! Abbey-Normal!" Grin. . . .

नमस्ते